Olon’s ability to develop and manufacture Active Pharmaceutical Ingredients (APIs) in our network of facilities allows clients full access to integrated services resulting in faster production and delivery timelines, with one of the most extensive track records.

We rely on synthetic and biological processes both for generic and contract development and the manufacturing market, in a full cGMPs environment, following ICH Q7 compliance.

With our structured expertise in chemical synthesis and microbial biomanufacturing, we are one of the most important players of API and HPAPI production, including controlled substances, innovative and generics drugs, advanced intermediates, enzymes, proteins, peptides and food biomanufacturing. Our sites are equipped with multi-purpose, dedicated lines where we can produce at different levels of high containment, up to OEB 5.

Our expertise is applied to the production of APIs for treatments used in many key therapeutic areas and for some breakthrough pharmaceutical products. We are leaders, among others, in the production of retinoids, antineoplastic, cardiovascular and metabolic diseases compounds, antibiotics and antivirals.